Cost analysis of biomarker testing for mismatch repair deficiency in node-positive colorectal cancer

British Journal of Surgery

Volumn 95, Issue 7, 2008, Pages 868-875

  Barrow, E ^a,b   McMahon, R ^a   Evans, D G ^b   Levine, E ^c   Hill, J ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE FREE SURVIVAL; DRUG COST; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NODE POSITIVE COLORECTAL CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; COLORECTAL TUMOR; ECONOMICS; GENETIC MARKER; GENETICS; LYMPH NODE METASTASIS; PREDICTION AND FORECASTING; REVIEW;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLORECTAL NEOPLASMS; COST SAVINGS; COST-BENEFIT ANALYSIS; DNA MISMATCH REPAIR; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MICROSATELLITE INSTABILITY; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS;

EID: 47249124795     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6172     Document Type: Conference Paper

References (44)

1. Cancer Research UK. UK Bowel Cancer Statistics. http://info.cancerresearchuk.org/cancerstats/types/bowel/ [accessed 1 May 2007].
2. Hayne D, Brown RS, McCormack M, Quinn MJ, Payne HA, Babb P. Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clin Oncol (R Coll Radiol) 2001; 13: 448-452.
3. Houlston RS. What we could do now: molecular pathology of colorectal cancer. Mol Pathol 2001; 54: 206-214.
4. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
5. Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998; 42: 673-679.
6. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000; 87: 1197-1202.
7. Rigau V, Sebbagh N, Olschwang S, Paraf F, Mourra N, Parc Y et al. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining. Arch Pathol Lab Med 2003; 127: 694-700.
8. Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 2002; 360: 1381-1391.
9. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
10. Ward RL, Turner J, Williams R, Pekarsky B, Packham D, Velickovic M et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2005; 207: 377-384.
11. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-2367.
12. Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de jong D et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005; 23: 5635-5643.
13. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-1206.
14. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-6875.
15. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58: 3455-3460.
16. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000; 156: 1773-1779.
17. Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159: 2107-2116.
18. Truninger K, Menigatti M, Luz J, Russell A, Haider R, Gebbers JO et al. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 2005; 128: 1160-1171.
19. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618.
20. Ward R, Meagher A, Tomlinson I, O'Connor T, Norrie M, Wu R et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001;48:821-829.
21. Cassidy J, DouillardJY, Twelves C, McKendrick JJ, Scheithauer W, Bustova I et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122-1129.
22. Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
23. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J med 2004; 350: 2343-2351.
24. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
25. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivify and resistance. Gastroenterology 2004; 127: 1678-1684.
26. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-131.
27. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-5201.
28. Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002; 15: 741-749.
29. Kerr DJ, Gray R, McConkey C, Barnwell J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules - less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann Oncoll 2000; 11: 947-955.
30. Wright CL, Stewart ID. Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol 2003; 27: 1393-1406.
31. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394-401.
32. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005; 11: 8332-8340.
33. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55: 848-855.
34. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355: 1745-1750.
35. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109: 468-471.
36. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-1071.
37. Valentini AM, Armentano R, Pirrelli M, Caruso ML. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer Treat Rev 2006; 32: 607-618.
38. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-3090.
39. des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 2007; 27: 2715-2719.
40. Fallik D, Borrini F, Boige V, Viguier J, Jacob S, Miquel C et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63: 5738-5744.
41. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 1043-1048.
42. Plaschke J, Kruger S, Pistorius S, Theissig F, Saeger HD, Schackert HK. Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. Int J Cancer 2002; 97: 643-648.
43. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-1860.
44. Aballea S, Boler A, Craig A, Wasan H. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer 2007; 43: 1687-1693.